ARTICLE | Company News
Matrix FDA panel set for Sept. 10
July 24, 2001 7:00 AM UTC
The FDA's Oncologic Drugs Advisory Committee will review on Sept. 10 MATX's NDA for its IntraDose cisplatin/epinephrine injectable gel to treat recurrent or refractory head and neck cancer. MATX submi...